Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial.

ABSTRACT:

Importance

Long-acting injectable antipsychotics (LAIs) can potentially reduce hospitalization risk by enhancing medication adherence but are rarely considered for early-phase schizophrenia treatment.

Objective

To determine whether encouraging use of a LAI compared with usual care delays the time to first hospitalization with patients with early-phase illness.

Design, setting, and participants

The Prevention of Relapse in Schizophrenia (PRELAPSE) trial was cluster randomized with a follow-up duration of 2 years. The study began in December 2014, was completed in March 2019, and was conducted in 39 mental health centers in 19 US states. Site randomization assigned 19 clinics to encourage treatment with long-acting aripiprazole monohydrate (aripiprazole once monthly [AO

SUBMITTER: Kane JM 

PROVIDER: S-EPMC7364341 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature